Navigation Links
The Non-Small-Cell Lung Cancer Drug Market Will Increase From Approximately $4 Billion in 2009 to More Than $6.5 Billion in 2019
Date:10/4/2010

BURLINGTON, Mass., Oct. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the non-small-cell lung cancer (NSCLC) drug market will increase from approximately $4 billion in 2009 to more than $6.5 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Non-Small-Cell Lung Cancer reveal that market growth will be driven by the increased uptake of Eli Lilly's Alimta and Genentech/OSI Pharmaceuticals/Roche/Chugai's Tarceva as well as the launches of premium-priced emerging therapies which include Sanofi-Aventis's iniparib, Boehringer Ingelheim's BIBW-2992 and Pfizer's crizotinib.

In 2009, antimetabolites dominated the NSCLC market with Alimta accounting for nearly three-quarters of sales within this drug class. Owing primarily to the generic erosion of Alimta and competition from emerging therapies, the market share of antimetabolites will decline. By 2019, the antimetabolites market share will be reduced to 24 percent, making it the second-largest drug class in NSCLC, while the epidermal growth factor receptor (EGFR) inhibitor class will garner a market share of 26 percent.

"The NSCLC drug market will continue to move toward personalized medicine through 2019, resulting in an increasingly fragmented market," said Decision Resources Analyst Janie Cox, Ph.D. "Treatments are becoming tailored to histology and clinical and molecular characteristics and targeted agents will have—at best—a modest patient share. However, their premium prices will ensure that they will garner significant market share."

The findings also reveal that in 2009, Alimta and Tarceva and Roche/Genentech/Chugai's Avastin were the leading therapies in NSCLC, capturing nearly two-thirds of overall sales. Through 2019, Alimta and Tarceva—which are increasingly being
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer
2. Dendreon Announces Presentation of PROVENGE Data at the 25th International Society for Biological Therapy of Cancer Annual Meeting
3. Elekta Launches ABAS 2.0 Autosegmentation Software Used to Plan Radiation Therapy in Patients With Cancer
4. Phase III Data Showing Improved Survival With Jevtana® (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
5. Surveyed European Oncologists Assign Greater Patient Share to Johnson & Johnsons Abiraterone Compared With Other Emerging Therapies in Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
6. Data Monitoring Committee Unanimously Recommends Continuation of Celsions Phase III ThermoDox® HEAT Study to Treat Primary Liver Cancer
7. FUJIFILM Revitalizes Images of Health Breast Cancer Awareness Initiative
8. Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports
9. Pfizer Discontinues Phase 3 Trial of SUTENT® in Advanced Castration-Resistant Prostate Cancer
10. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
11. The Japanese Cancer Association and Debiopharm Group(TM) Present the JCA-Mauvernay Award to Dr Ogawa and Prof. Maeda for Their Outstanding Oncology Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... LONDON , Sept. 16, 2014 ... wound closure market, Frost & Sullivan recognises Incisive ... Award for Customer Value Leadership. Incisive Surgical,s uniquely-designed, ... closure technology that eliminates the need for patients ... punctures and staple removal  that may result in ...
(Date:9/16/2014)... , Sept. 16, 2014 CorMedix Inc. ... on developing and commercializing therapeutic products for the ... diseases, announces the amendment and restatement of its ... stock and related warrants, as well as the ... and warrant financing, to remove anti-dilution, price reset ...
(Date:9/16/2014)...  DNAtrix, Inc., experts in oncolytic virus development, ... with the company,s lead product, DNX-2401, a replication ... multicenter, open-label Phase Ib study for patients with ... leading neurosurgeons and neuro-oncologists in the US, is ... Phase Ib study of DNX-2401 at Moffitt Cancer ...
Breaking Medicine Technology:Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 2Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 3Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 4Frost & Sullivan Commends Incisive Surgical for Delivering Superior Customer Value through its Patient-Centric, Cost-Effective INSORB Absorbable Stapler 5CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 2CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification 3DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial 2
... ALTO, Calif., Dec. 21, 2010 Jazz Pharmaceuticals, Inc. ... United States Patent and Trademark Office (USPTO) has issued ... titled "Microbiologically Sound and Stable Solutions of Gamma-Hydroxybutyrate Salt ... 7,851,506, is also listed in the FDA,s Approved Drug ...
... Today, Pepex Biomedical, Inc. announced that the company has ... Therapeutic Discovery Project created by Congress as a component ... 2010, the major health care reform bill, signed into ... submitted their ground-breaking, patented, electrochemical biosensor, nanotechnology and the ...
Cached Medicine Technology:Jazz Pharmaceuticals Announces New Patent Issued for Sodium Oxybate 2Pepex™ Awarded Qualifying Therapeutic Discovery Project Grant 2
(Date:9/16/2014)... Dotinga HealthDay Reporter , MONDAY, ... baldness may face a higher risk of developing an aggressive ... new study suggests. But, the study authors noted that ... of baldness should be concerned. Their study only found an ... did not prove cause and effect. "It is conceivable ...
(Date:9/16/2014)... After working together for eight years and ... fertility centers in the late 1990s and early 2000s, Dr. ... hometown of New York City to launch Chelsea Fertility of ... , Chelsea Fertility NYC offers full service fertility treatment ... New York Tri-State Area, and provides equal access to care ...
(Date:9/16/2014)... New Jersey (PRWEB) September 16, 2014 ... Infinity Development Partners of San Antonio, TX. has been ... Army facilities located throughout the US, including Alaska and ... Army’s Energy Initiatives Task Force (EITF) and the Corps ... a $7 Billion MATOC primarily to fund renewable and ...
(Date:9/16/2014)... Alachua, FL (PRWEB) September 16, 2014 ... technology company focused on the peripheral nerve repair market, ... the American Society for Surgery of the Hand (ASSH) ... John B. Hynes Convention Center in Boston, MA. , ... outcomes in surgical nerve repair, featuring a discussion by ...
(Date:9/16/2014)... September 16, 2014 Much of the ... major extended drought crisis that in many regions affects ... the many individuals who are dedicated to solving the ... solutions overlook large portion of the problem. Partial solutions, ... crises.     , Grigg explained his, “total water management” concept ...
Breaking Medicine News(10 mins):Health News:Male Pattern Baldness Tied to Prostate Cancer, Study Suggests 2Health News:Male Pattern Baldness Tied to Prostate Cancer, Study Suggests 3Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 2Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 3Health News:Chelsea Fertility NYC Offers New and Affordable Fertility Treatment Options for Patients in the New York Tri-State Area 4Health News:Solar Construction Opportunity at U.S Army Installations Awarded to Pfister Energy & Infinity Development 2Health News:AxoGen, Inc. to Host Surgeon Education Event at American Society for Surgery of the Hand 2014 Annual Meeting 2Health News:AxoGen, Inc. to Host Surgeon Education Event at American Society for Surgery of the Hand 2014 Annual Meeting 3Health News:Drought Solutions Overlook Too Many Factors Water Policy Expert Warns Sharon Kleyne 2Health News:Drought Solutions Overlook Too Many Factors Water Policy Expert Warns Sharon Kleyne 3
... men after bypass surgery, according to a new study done ... say whether the //results are due to medical or psychosocial ... outcomes after bypass surgery than men. Most have attributed this ... generally older, sicker, and have fewer social supports. In this ...
... is when symptoms have lasted for less than three ... self-management program that includes group classes, exercise sheet handouts, ... manage their back pain. ,Researchers from Indiana University ... low back pain. The program focuses on boosting confidence ...
... study shows hydrotherapy, or water exercise, may improve strength and ... studied more than 100 patients with osteoarthritis who were older ... first group exercised three times a week in a swimming ... did not exercise at all. Both the water and gym ...
... may improve strength and mobility in patients with osteoarthritis.// ... who were older than age 50. Patients were divided into ... in a swimming pool, the second exercised in a gym, ... water and gym programs focused on resistance exercises. ,Results ...
... lasted for less than three months. ,A new study ... sheet// handouts, and telephone follow-up calls may help patients ... from Indiana University developed a self-management program for poor, ... on boosting confidence in order to increase their motivation ...
... reducing the signs of aging in the neck. The procedure involves ... reduce the saggy appearance of the neck. Researchers say this new ... are often changes in the neck and face including the loss ... of fat in the neck. This causes the skin to sag. ...
Cached Medicine News:
Inquire...
... Roches patented polymerase chain reaction (PCR) ... technology, is an essential component of Roches ... PCR allows minute amounts of selected unique ... into billions of copies (that is, to ...
... Introducing BenchMark XT® the only fully ... flexibility you need to expand your ... improve your slide turnaround time. All ... choose how to use the BenchMark ...
... Reicherts new ATP Auto Non-Contact Tonometer / ... / pachymeter, combining the measurement of IOP ... response to numerous clinical studies that have ... thickness as well as intraocular pressure in ...
Medicine Products: